close

A.P. Pharma, Inc., a specialty pharmaceutical company, engages in developing pharmaceutical products using its proprietary Biochronomer polymer-based drug delivery technology. Its lead product candidate is APF530, which completed pivotal Phase III clinical trial for the prevention of chemotherapy-induced nausea and vomiting. The company's product candidate also includes APF112, which incorporates anesthetic, mepivacaine and is designed to provide relief from post-surgical pain and to minimize the use of morphine-like drugs, or opiates. Its pre clinical product candidate APF580 incorporates an opiate into its Biochronomer technology and is designed to provide analgesia lasting at least seven days from a single injection. A.P. Pharma's Biochronomer technology is also used for various applications in therapeutic areas, including pain management, prevention of nausea, control of inflammation, and treatment of ophthalmic diseases. The company was formerly known as Advanced Polymer Systems, Inc. and changed its name to A.P. Pharma, Inc. in May 2001. A.P. Pharma, Inc. was founded in 1983 and is based in Redwood City, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	9999.99
Volume	143049
Volume Avg	(mio) 1063.68
52 Week High	0.12
52 Week Low	0.00
PE	N/A
PE (group average)	39
EPS Year	0.00
EPS change Q/Q	0%
EPS change Q/Q Yr ago	-20%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-77.78%
REV change Q/Q	-50%
REV change Q/Q Yr ago	100%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%